Key Points
Wolfe Research maintained Outperform on TMHC, raising price target to $76
Taylor Morrison trades at attractive 9.2x P/E with zero debt and strong cash flow
Meyka AI rates TMHC B+ with 8 Buy ratings from Wall Street consensus
Stock offers 17.9% upside potential with solid residential construction fundamentals
Wolfe Research maintained its Outperform rating on Taylor Morrison Home Corporation (TMHC) on April 23, 2026, while raising the price target to $76 from $73. The homebuilder trades at $64.33 with a market cap of $6.2 billion. This TMHC analyst rating reflects confidence in the residential construction company’s fundamentals. The stock has gained 9.24% year-to-date and trades at a 9.2x P/E ratio, suggesting relative value in the sector. Meyka AI rates TMHC with a grade of B+, indicating solid fundamentals and growth potential.
Wolfe Research Maintains Outperform on TMHC
Wolfe Research kept its Outperform rating intact while boosting the price target by $3 per share. The analyst firm sees upside potential from current levels. TMHC trades below the new target, offering a 17.9% upside to the $76 price objective. The stock closed at $64.33 on the rating date, down 0.67 from the prior close. This TMHC analyst rating reflects steady execution in home construction and favorable market conditions for residential builders.
Strong Valuation Metrics Support Rating
Taylor Morrison trades at an attractive 0.81x price-to-sales ratio and 9.2x P/E, well below historical averages. The company’s $6.2 billion market cap positions it as a mid-cap homebuilder with significant scale. Book value per share stands at $65.06, while the stock trades at 0.99x book value. These metrics suggest the market has priced in modest growth expectations. The valuation supports Wolfe’s constructive stance on TMHC analyst rating fundamentals.
Financial Health and Cash Generation
Taylor Morrison demonstrates robust financial strength with zero debt-to-equity ratio and a 26.8x current ratio. Operating cash flow reached $7.83 per share trailing twelve months, while free cash flow totaled $7.39 per share. The company generates strong returns on equity at 10.8% and return on assets of 6.9%. Interest coverage of 20.2x shows the builder can easily service obligations. This TMHC analyst rating reflects confidence in the company’s ability to fund growth and shareholder returns.
Revenue and Profitability Trends
Taylor Morrison reported $79.27 in revenue per share over the trailing twelve months. Net profit margin stands at 8.8%, while operating margin reaches 13.2%. The company’s $6.8 billion in working capital provides flexibility for operations and acquisitions. Gross profit margin of 22.4% reflects pricing power in the residential market. Wolfe Research raised the price target to $76, citing these operational strengths and market tailwinds.
Meyka AI Grade and Market Positioning
Meyka AI rates TMHC with a grade of B+, reflecting solid fundamentals and growth potential. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score of 75.6 out of 100 places Taylor Morrison in the upper-middle tier of homebuilders. The rating suggests the stock offers balanced risk-reward for investors seeking residential construction exposure. These grades are not guaranteed and we are not financial advisors.
Analyst Consensus and Sector Outlook
Wall Street consensus shows 8 Buy ratings, 1 Hold, and zero Sell ratings on TMHC. The average rating translates to a Buy recommendation across the analyst community. Taylor Morrison operates in the Consumer Cyclical sector within Residential Construction. The company builds homes under the Taylor Morrison, William Lyon Signature, and Darling Homes brands across ten states. TMHC benefits from favorable housing demand and limited supply in key markets.
Technical Setup and Price Momentum
TMHC trades near its 50-day moving average of $61.57 and above the 200-day average of $62.88. The stock has climbed 9.2% over five days and 8.4% in one month, showing positive momentum. Year-to-date performance stands at 9.24%, outpacing broader market weakness. The 52-week range spans $54.58 to $72.50, with the stock trading in the upper half of that range. Technical strength supports the Outperform rating from Wolfe Research.
Volume and Trading Activity
Average daily volume reaches 1.26 million shares, while recent volume hit 1.71 million shares, indicating strong interest. The relative volume ratio of 1.14x shows above-average trading activity. RSI stands at 62.4, suggesting the stock has room to run without being overbought. MACD shows positive momentum with a histogram of 0.82. These technical signals align with the constructive TMHC analyst rating from Wolfe Research.
Final Thoughts
Wolfe Research’s maintained Outperform rating and raised $76 price target reflect confidence in Taylor Morrison’s residential construction business. The homebuilder trades at attractive valuations with strong cash generation and zero debt. TMHC’s B+ Meyka grade and 8 Buy ratings from Wall Street underscore positive sentiment. The stock offers 17.9% upside to the new target, supported by favorable housing fundamentals and operational execution. Investors seeking residential construction exposure should monitor quarterly earnings and housing demand trends. The TMHC analyst rating from Wolfe Research remains constructive for the near term.
FAQs
Wolfe Research raised its price target to **$76 from $73** on April 23, 2026. This represents **17.9% upside** from the stock’s trading price of **$64.33**. The TMHC analyst rating remains at Outperform.
Wall Street consensus shows **8 Buy ratings and 1 Hold** on TMHC, translating to a **Buy** recommendation. No analysts rate the stock as Sell. This TMHC analyst rating reflects broad optimism about the homebuilder’s prospects.
Meyka AI rates TMHC with a **B+ grade** based on S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. The score of **75.6** suggests solid fundamentals. These grades are not guaranteed and we are not financial advisors.
TMHC trades at **0.81x price-to-sales** and **9.2x P/E**, below historical averages. The stock trades at **0.99x book value** of **$65.06 per share**. These metrics suggest the TMHC analyst rating reflects attractive valuation relative to growth prospects.
Taylor Morrison has **zero debt-to-equity**, **26.8x current ratio**, and **$7.83 operating cash flow per share**. Return on equity reaches **10.8%** with **8.8% net margin**. These metrics support the Outperform TMHC analyst rating from Wolfe Research.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)